These treatments may become valuable tools for maintaining cognitive health while addressing metabolic concerns
These patterns have led many scientists to frame AD as a brain-specific insulin-resistant state , colloquially type 3 diabetes. While not every expert embraces the term, multiple recent reviews detail the mechanistic links
Here is who benefits most: Good fit if you: Qualify for GLP-1 medication (BMI 30+ or BMI 27+ with a weight-related condition) Want behavioral coaching alongside medication, not just a prescription Prefer a structured program with lessons, food logging, and community support Have tried medication alone and struggled with side effects or regain Want compounded medication shipped to your door (avoiding pharmacy visits) Not a good fit if you: Want the cheapest way to get a GLP-1 prescription (Ro and similar services are less expensive for medication-only access) Already have strong nutrition habits and just need the drug Live in Alabama, Louisiana, Mississippi, or Virginia (some programs unavailable) Have a history of medullary thyroid cancer, multiple endocrine neoplasia 2, or active gastrointestinal conditions like gastroparesis Want brand-name medication but do not have insurance to cover it (the out-of-pocket drug cost makes it very expensive) How Noom Med Compares to Alternatives The GLP-1 telehealth space has gotten crowded
cAMP Promotes Pancreatic Beta-Cell Survival Via CREB-mediated Induction of IRS2
Barrett 23:14 Yeah, let's try
By inhibiting glucagon release from pancreatic alpha cells, Semaglutide helps prevent excessive production of glucose in the liver
